Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report

RATIONALE: Dapagliflozin (a sodium-glucose cotransporter-2 [SGLT2] inhibitor) represents the most recently approved class of oral medications for the treatment of type 2 diabetes. Dapagliflozin lowers plasma glucose concentration by inhibiting the renal reuptake of glucose in the proximal renal tubu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeo, Sang Mok, Park, Hayeon, Paek, Jin Hyuk, Park, Woo Yeong, Han, Seungyeup, Park, Sung Bae, Jin, Kyubok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370067/
https://www.ncbi.nlm.nih.gov/pubmed/30653152
http://dx.doi.org/10.1097/MD.0000000000014150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370067/
https://www.ncbi.nlm.nih.gov/pubmed/30653152
http://dx.doi.org/10.1097/MD.0000000000014150

Ejemplares similares